Restricted accessResearch articleFirst published online 2023-6
Impact of a Multicomponent Educational Intervention on Community Pharmacy–Based Naloxone Services Implementation: A Pragmatic Randomized Controlled Trial
Despite US naloxone access laws, community pharmacists lack training and confidence in providing naloxone.
Objective:
To assess the impact of the Empowering Community Pharmacists program on pharmacists’ knowledge, perceived barriers, attitudes, confidence, and intentions regarding naloxone services implementation, as well as naloxone prescriptions dispensed.
Methods:
A 3-month pragmatic randomized controlled trial was conducted from December 2018 to March 2019. Alabama community pharmacists were recruited by mail, email, phone, and fax and randomized to intervention (monthly resources/reminders + educational webinar) or control (monthly reminders only). Outcome measures were assessed via online surveys at baseline (T1), immediately post-intervention (T2), and 3 months post-intervention (T3), including naloxone knowledge (%correct); perceived barriers, attitudes, confidence, and intention regarding naloxone services implementation (7-point Likert-type scale; 1 = strongly disagree, 7 = strongly agree); and number of naloxone prescriptions dispensed. Mean differences between control and intervention from T1 to T3 were assessed using 2-way mixed analysis of variance and adjusted analyses were conducted using generalized estimating equations with negative binomial distribution to assess associations between variables.
Results:
Of 55 participants (n = 27 intervention, n = 28 control), most were female (80.3%), white (80.6%), in independently owned pharmacies (39.1%). Increases in mean [SD] confidence (5.52 [1.03]-6.16 [0.74], P < 0.0005) and intention (5.35 [1.51]-6.10 [0.96], P = 0.023) occurred from pre- to post-program within the intervention group and were statistically significant compared with control (confidence P = 0.016, intention P = 0.014). Confidence (exp(β) = 1.46, P = 0.031) and perceived barriers (exp(β) = 0.75, P = 0.022) were associated with number of naloxone prescriptions dispensed.
Conclusion and Relevance:
The Empowering Community Pharmacists program improved community pharmacists’ confidence and intention regarding naloxone services implementation. Other states can adapt program elements according to their laws.
BaileyAMWermelingDP. Naloxone for opioid overdose prevention: pharmacists’ role in community-based practice settings. Ann Pharmacother. 2014;48:601-606. doi:10.1177/1060028014523730.
GrabensteinJD. Pharmacists as vaccine advocates: roles in community pharmacies, nursing homes, and hospitals. Vaccine. 1998;16(18):1705-1710. doi:10.1016/S0264-410X(98)00131-5.
BaileyAMWermelingDP. Naloxone for opioid overdose prevention: pharmacists’ role in community-based practice settings. Ann Pharmacother. 2014;48(5):601-606. doi:10.1177/1060028014523730.
JonesCMLuriePGComptonWM. Increase in naloxone prescriptions dispensed in US retail pharmacies since 2013. Am J Public Health. 2016;106(4):689-690. doi:10.2105/AJPH.2016.303062.
15.
ZallerNDYokellMAGreenTCGagginJCaseP. The feasibility of pharmacy-based naloxone distribution interventions: a qualitative study with injection drug users and pharmacy staff in Rhode Island. Subst Use Misuse. 2013;48(8):590-599. doi:10.3109/10826084.2013.793355.
16.
WalleyAYGreenTC. Mainstreaming naloxone through coprescription to patients receiving long-term opioid therapy for chronic painnaloxone coprescription to patients receiving long-term opioid therapy. Ann Intern Med. 2016;165(4):292-293. doi:10.7326/M16-1348.
17.
CoffinPOBeharERoweC, et al. Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for PainNaloxone coprescribing in primary care clinics. Ann Intern Med. 2016;165(4):245-252. doi:10.7326/M15-2771.
18.
RaischDWFudalaPJSaxonAJ, et al. Pharmacists and technicians; perceptions and attitudes toward dispensing buprenorphine/naloxone to patients with opioid dependence. J Am Pharm Assoc. 2005;45(1):23-32. doi:10.1331/1544345052843200.
19.
PalmerEHartSFreemanPR. Development and delivery of a pharmacist training program to increase naloxone access in Kentucky. J Am Pharm Assoc. 2017;57(2):S118-S122. doi:10.1016/j.japh.2016.12.071.
20.
EukelHNSkoyEWerremeyerABurckSStrandM. Changes in pharmacists’ perceptions after a training in opioid misuse and accidental overdose prevention. J Contin Educ Health Prof. 2019;39(1):7-12. doi:10.1097/CEH.0000000000000233.
21.
CarpenterDMRobertsCAWestrickSC, et al. A content review of online naloxone Continuing Education courses for pharmacists in states with standing orders. Res Social Adm Pharm. 2018;14(10):968-978. doi:10.1016/j.sapharm.2017.11.011.
22.
GreenTCBratbergJIrwinAN, et al. Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies. Subst Abus. 2022;43(1):901-905. doi:10.1080/08897077.2021.2010162.
HohmannLFoxBPhillippeHMMarloweKHillSFowlerA. A community-wide education program on drug addiction: stakeholder knowledge, beliefs, and opportunities for interprofessional collaboration. Value Health. 2018;21:S189-S190. doi:10.1016/j.jval.2018.04.1276.
25.
HohmannLADiggsKFoxBI, et al. Empowering community pharmacists to prevent opioid overdose deaths: a qualitative study exploring pharmacists’ needs, attitudes, barriers, and implementation strategies regarding pharmacy-based naloxone services. Abstract presented at American Pharmacists Association Annual Meeting and Exposition; March 2019; Seattle, WA.
26.
ZwarensteinMTreweekSGagnierJJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337:a2390. doi:10.1136/bmj.a2390.
27.
Centers for Disease Control and Prevention, National Center for Health Statistics. Compressed Mortality File 1999-2014 on CDC WONDER online database, released December 2015. Data are from the Compressed Mortality File 1999-2014 Series 20 No. 2T, 2015, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Published 2015. http://wonder.cdc.gov/cmf-icd10.html.
HealthCare.gov. Full-time employee (FTE)—HealthCare.gov glossary. Published 2022. Accessed May 12, 2022. http://HealthCare.gov.
30.
LegrisMÈSéguinNCDesforgesK, et al. Pharmacist web-based training program on medication use in chronic kidney disease patients: impact on knowledge, skills, and satisfaction. J Contin Educ Health Prof. 2011;31(3):140-150. doi:10.1002/chp.20119.
31.
CainWTCableGOppenheimerJJ. The ability of the community pharmacist to learn the proper actuation techniques of inhaler devices. J Allergy Clin Immunol. 2001;108(6):918-920. doi:10.1067/mai.2001.119153.
ChungCPCallahanSTCooperWO, et al. Outpatient opioid prescriptions for children and opioid-related adverse events. Pediatrics. 2018;142(2):e20172156. doi:10.1542/peds.2017-2156.
35.
HigginsCSmithBHMatthewsK. Incidence of iatrogenic opioid dependence or abuse in patients with pain who were exposed to opioid analgesic therapy: a systematic review and meta-analysis. Br J Anaesth. 2018;120(6):1335-1344. doi:10.1016/j.bja.2018.03.009.
HillLGSanchezJPLaguadoSALawsonKA. Operation Naloxone: overdose prevention service learning for student pharmacists. Curr Pharm Teach Learn. 2018;10(10):1348-1353. doi:10.1016/j.cptl.2018.07.010.
39.
NielsenSMenonNLarneySFarrellMDegenhardtL. Community pharmacist knowledge, attitudes and confidence regarding naloxone for overdose reversal. Addiction. 2016;111(12):2177-2186. doi:10.1111/add.13517.
40.
UrmieJMFarrisKBHerbertKE. Pharmacy students’ knowledge of the Medicare drug benefit and intention to provide Medicare medication therapy management services. Am J Pharm Educ. 2007;71(3):41. doi:10.5688/aj710341.
41.
WilliamsAVStrangJMarsdenJ. Development of Opioid Overdose Knowledge (OOKS) and Attitudes (OOAS) Scales for take-home naloxone training evaluation. Drug Alcohol Depend. 2013;132(1-2):383-386. doi:10.1016/j.drugalcdep.2013.02.007.
42.
de WinterJCFDodouDWieringaPA. Exploratory factor analysis with small sample sizes. Multivariate Behav Res. 2009;44(2):147-181. doi:10.1080/00273170902794206.
43.
WaltzTJPowellBJMatthieuMM, et al. Use of concept mapping to characterize relationships among implementation strategies and assess their feasibility and importance: results from the Expert Recommendations for Implementing Change (ERIC) study. Implementation Science. 2015;10(1):109.
44.
WagnerKDBovetLJHaynesBJoshuaADavidsonPJ. Training law enforcement to respond to opioid overdose with naloxone: impact on knowledge, attitudes, and interactions with community members. Drug Alcohol Depend. 2016;165:22-28. doi:10.1016/j.drugalcdep.2016.05.008.
45.
KlimasJEganMTobinHColemanNBuryG. Development and process evaluation of an educational intervention for overdose prevention and naloxone distribution by general practice trainees. BMC Med Educ. 2015;15:206. doi:10.1186/s12909-015-0487-y.
46.
NielsenSPiccoLKowalskiM, et al. Routine opioid outcome monitoring in community pharmacy: outcomes from an open-label single-arm implementation-effectiveness pilot study. Res Social Adm Pharm. 2020;16(12):1694-1701. doi:10.1016/j.sapharm.2020.02.009.
47.
ThakurTChewningB. Pharmacists opioid risk and safety counseling practices: a latent class analysis approach. Res Social Adm Pharm. 2022;18:3013-3018. doi:10.1016/j.sapharm.2021.07.023.
ThakurTFreyMChewningB. Evaluating pharmacy student consultations on opioid medication use and discussion of opioid-specific risks. Am J Pharm Educ. 2019;85(8):7494. doi:10.5688/ajpe7494.
50.
SeybertAL. Patient simulation in pharmacy education. Am J Pharm Educ. 2011;75(9):187. doi:10.5688/ajpe759187.
51.
StewartBThomasRLTutag-LehrV. Pharmacists’ knowledge, support, and perceived roles associated with providing naloxone in the community. Curr Pharm Teach Learn. 2018;10(8):1013-1021. doi:10.1016/j.cptl.2018.05.016.
52.
PolliniRASlocumSOzgaJ, et al. Pharmacists’ experiences with a statewide naloxone standing order program in Massachusetts: a mixed methods study. J Am Pharm Assoc. 2022;62(1):157-166. doi:10.1016/j.japh.2021.08.020.
53.
GreenTCCasePFiskeH, et al. Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states. J Am Pharm Assoc. 2017;57(2):S19-S27.e14. doi:10.1016/j.japh.2017.01.013.
54.
FrankoTSIIDistefanoDLewisL. A novel naloxone training compared with current recommended training in an overdose simulation. J Am Pharm Assoc. 2019;59(3):375-378. doi:10.1016/j.japh.2018.12.022.
55.
MortonKJHarrandBFloydCC, et al. Pharmacy-based statewide naloxone distribution: a novel “top-down, bottom-up” approach. J Am Pharm Assoc. 2017;57(2):S99-S106. doi:10.1016/j.japh.2017.01.017.
56.
LimJKBratbergJPDavisCSGreenTCWalleyAY. Prescribe to prevent: overdose prevention and naloxone rescue kits for prescribers and pharmacists. J Addict Med. 2016;10(5):300-308. doi:10.1097/ADM.0000000000000223.
CarpenterDMDhamanaskarAKGallegosKLShepherdGMosleySLRobertsCA. Factors associated with how often community pharmacists offer and dispense naloxone. Res Social Adm Pharm. 2019;15(12):1415-1418. doi:10.1016/j.sapharm.2018.07.008.
59.
GandhiNHanesSCandelarioDMCloughCHighlandJ. Impact of a communication technique training on rates of naloxone dispensing. J Am Pharm Assoc. 2020;60(suppl 3):S37-S40. doi:10.1016/j.japh.2020.02.006.
60.
Jean-Venable KellyRGoode MottDAChaterR. Collaborations to facilitate success of community pharmacy practice-based research networks. J Am Pharm Assoc. 2008;48(2):153-162. doi:10.1331/JAPhA.2008.07139.
61.
LipowskiEE. Pharmacy practice-based research networks: why, what, who, and how. J Am Pharm Assoc. 2008;48(2):142-152. doi:10.1331/JAPhA.2008.08018.
62.
CarrMBDivineHHannaCFreemanPRBlumenscheinK. Independent community pharmacist interest in participating in community pharmacy research networks. J Am Pharm Assoc. 2011;51(6):727-733. doi:10.1331/JAPhA.2011.10099.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
